MIRA secures worldwide rights for Ketamir-2, expands IP to 10 markets ahead of Phase 2a

MIRA PHARMACEUTICALS, INC.

Amendment expands licensed territory from US, Canada, Mexico to all countries with patent rights.
IP portfolio now covers filings in 10 markets: US, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, S. Korea.
Core economic terms (royalties, financial consideration) of original license agreement unchanged.
Company advancing Phase 2a protocol for FDA submission after positive Phase 1 data in 56 volunteers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MIRA PHARMACEUTICALS, INC. amended Amendment No. 1 to Exclusive License Agreement with MIRALOGX LLC valued at Expanded exclusive licensed territory from US, Canada, Mexico to all countries with patent rights; e (effective 2026-05-21).

Action: amendment
Agreement: license
Counterparty: MIRALOGX LLC
Value: Expanded exclusive licensed territory from US, Canada, Mexico to all countries with patent rights; e
Effective: 2026-05-21

Exact text from the filing

On May 21, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Exclusive License Agreement, effective November 15, 2023, by and between the Company and MIRALOGX LLC.

View on SEC.gov

Browse all material agreements →

MIRA PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-025335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.